about
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to ExpectMultidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox.Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DCHPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cellsInduction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccinationSampling site matters when counting lymphocyte subpopulations.Clinical use of dendritic cells for cancer therapy.Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials.Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential.Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner.Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancerGeneration of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cellsImmunotherapy of acute myeloid leukemia: current approaches.Dendritic cell-based cancer gene therapy.Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?Natural killer cell immune escape in acute myeloid leukemia.NK cells: key to success of DC-based cancer vaccines?Tumoricidal activity of human dendritic cells.Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs.Interleukin-15: new kid on the block for antitumor combination therapy.CD70: An emerging target in cancer immunotherapy.Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy.Targeting immune checkpoints: New opportunity for mesothelioma treatment?Inborn errors in RNA polymerase III underlie severe varicella zoster virus infections.Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity.CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation.Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities.The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cellsmRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells.
P50
Q26775578-58DA5386-1332-46B8-9CE3-5274C9CD39C0Q33683179-6C4DEF03-588C-4EC7-93C2-FE4683BFB901Q33940675-2C915BF3-E954-48C4-A868-5F456D7853B9Q34011491-EF9D0B71-BC6E-4512-8CA5-798CDF237520Q34068404-97D52F2F-E294-411D-A251-46053DDDE3DEQ34358436-5FC7588A-8C1F-4049-9D12-72D344A82467Q34421850-1869350C-179A-4E15-B4F9-564372296E10Q34503435-57DC0A54-3EB1-4349-A2B4-49EBB51E1540Q34532389-33999450-46AC-488B-B4C3-22DADEF7AE3CQ35624376-B0BCF001-0769-4CC9-A1DB-8627401BF35EQ35817394-48F2B458-5978-46E8-B31B-FF24856042FAQ35955354-17BF3211-1919-42B5-A11C-F6DA476C8695Q36107961-C259A259-CB29-4AE5-85D7-C19830313002Q36396832-539191F3-A8BF-49F9-BE02-4033886E60E9Q37294760-BF23E36D-0200-4B53-8B8F-30F1E10E50E8Q37415836-792766E8-8F58-4476-91D3-2696E35E84F0Q37572777-2E3382C8-EBBD-485D-8D6D-2960A3D0F387Q37643309-367B63CB-2FBB-45D1-AE70-930AB5020C2AQ37945301-8BDF2D59-1B2A-4548-843C-07984414A23EQ37996816-264C88E2-6C5B-4D50-A1F9-45A7098A0F1CQ38036202-8F4798CC-7148-41DB-96B8-BE9B7CB17713Q38164916-109DDA29-6C95-4183-B77C-D62A1A3E99B8Q38242271-155D2D71-0A0E-4E1B-A612-DC3EC0A05BB9Q38256660-DB64FBC7-78A5-4338-8E9C-FB8425CB8710Q38259216-B1FF96B6-66C9-4209-AE09-5F74394B36F8Q38554834-2BD8257B-9398-429C-A0E1-437169382BDEQ38560389-52059976-5A7C-4E00-8A45-873262EFD46DQ38598419-5278C785-B23B-45A7-8FB0-F8F38FF1F919Q38637282-EC9BA8B8-311D-4D72-AF96-2F02A84F1DA7Q38714989-27001BDF-FAFB-4F47-AD07-E8C5E304744BQ38730777-228D4857-4C3B-4AFF-9735-867880DC1899Q38850275-F01244C1-A280-4B90-9577-DD22E98FF5CCQ38961442-33146260-129E-4BB6-8DB9-0D89B887D903Q38989782-B8EB29A9-45A3-4F23-81CD-8964F2B09DA2Q39014899-A3765698-2D64-489A-94C1-E6D83CBC89C2Q39015531-86AF9BB1-80C0-4A21-B23F-D72C63617620Q39281392-605FD856-7DC2-403C-A11F-A116312C81D9Q39360428-B7A6D57C-9E74-4CBD-A0E4-3DDEF60810CBQ39550591-D0D46809-4EFF-45E7-8609-17E16CBCB8B3Q39930816-77CF7C07-7F25-4AF9-8ED5-220171CFA71D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
E Smits
@ast
E Smits
@en
E Smits
@es
E Smits
@nl
type
label
E Smits
@ast
E Smits
@en
E Smits
@es
E Smits
@nl
prefLabel
E Smits
@ast
E Smits
@en
E Smits
@es
E Smits
@nl
P106
P31
P496
0000-0001-9255-3435